About Us

Director

Paul Cronin is a Director and an integral member of the leadership team at Scendea. Alongside his position as Director, Paul manages Scendea’s global business development team. Paul has over 20 years’ experience in the pharmaceutical industry holding senior positions at several regulatory and clinical research companies including ERA Consulting, SMERUD Medical Research and Diamond Pharma Services.

Paul began his pharmaceutical career as a Regulatory Affairs/Product Development Consultant, thereafter, moving into business and corporate development. Paul has several advisory board roles and holds degrees in Biochemistry and International Business and Management.

Managing Director (UK & EU) & Chief Financial Officer

Charles Camp is a Managing Director (UK & EU) and Chief Financial Officer and a member of the leadership team at Scendea. Charles is responsible for Scendea’s back office functions in addition to the strategic financial aspects of the business.

Prior to joining Scendea, Charles’ experience includes international expansion, key financial analysis, strategic planning and system implementation, specialising in investment and scenario modelling. Charles has worked in both a technical and commercial capacity, relishing the problem solving obligations inevitable in all SME’s. Charles is a Chartered Global Management Accountant and holds a BA in Business Management.

Managing Director (AUS) & Global Head of QA

Susan Jones is the Managing Director (AUS) & Global Head of QA at Scendea, responsible for the Quality Management System, process improvement including internal audits and leading the development of Scendea's training program.

Susan has over 25 years’ experience in the CRO industry, including various director roles in operations, quality and vendor management. Sue was the Director of Quality at CNS, where she established the quality group and was responsible for developing the QMS, training, and performing internal as well as local and international contracted audits. Sue holds a BAppSci and is a member of the RQA.

Chief Business Officer

Mike Mulcahy is the Chief Business Officer at Scendea, responsible for leading our growing business development team and defining Scendea’s global commercial strategy.

With over 30 years of experience working with international teams, Mike brings a wealth of expertise in strategic, technical, scientific, commercial, program, and business management for a broad range of technologies and services for therapeutic and medical device development, manufacturing, and supply for major markets. Mike holds an MBA and a BSc in Industrial Chemistry.

Head of Product Development & Regulatory Consulting, Principal Consultant

Zeb Younes is Head of Product Development & Regulatory Consulting, Principal Consultant at Scendea with over 20 years’ experience in biopharmaceutical development. Zeb has experience with tissue, cell and gene therapies, vaccines, recombinant proteins including enzymes, hormones, monoclonal antibodies and their derivatives and has authored and supported preparation and review of scientific advice briefing packages, orphan designation applications and IND/IMPD/BLA/MAA dossiers.

Zeb has extensive experience interacting with the FDA, EMA and other regulatory agencies such as EU nationals, ANVISA and Health Canada for scientific advice discussions and has over 10 years’ experience managing research teams, GMP testing laboratories and operations. Zeb sits on the editorial board for the TOPRA regulatory rapporteur and holds a 1st in Class BSc (Hons) in Medical Biochemistry.

Chief Medical Officer

Dr Robert Dow is the Chief Medical Officer at Scendea, responsible for providing technical/regulatory advice and product development strategies. Robert was formerly the CMO at PPD and has over 37 years’ experience in pharmaceutical and biotech industry. Robert has held a variety of executive positions including at PPD, Syntex, Hoffman La Roche, and Cell Genesys.

Robert has substantial experience in managing the transition of medicinal products from pre-clinical to clinical development and has experience in the fields of toxicology, pharmacokinetics, clinical science, clinical operations, regulatory affairs and drug safety. Robert holds a BSc (Med.Sci), a MB ChB, a MRCP (UK) and is a Fellow of the Royal College of Physicians of Edinburgh.

Principal Medical Consultant & Deputy Chief Medical Officer

Dr Krassimira Ourumova is a Principal Medical Consultant and Deputy Chief Medical Officer at Scendea. Krassimira provides both scientific, regulatory and clinical development advice and product development strategies to our clients.

Krassimira has 10 years of experience in clinical practice and over 25 years in pharmaceutical and biotech industry covering all aspects of pharmaceutical product development with a focus in clinical science and operations. Krassimira has extensive experience interacting with the FDA, EMA and a number of national regulatory authorities. Krassimira has held a variety of leadership positions including at MSD, GSK Bio and Daiichi Sankyo. Krassimira is a Medical Doctor certified in Anaesthesiology and Intensive Care.

Principal Medical Consultant

Dr Paul Griffin is a Principal Medical Consultant at Scendea, offering invaluable technical, scientific, and clinical development guidance to our clients. With extensive experience as a Principal Investigator and Medical Monitor, Paul is a renowned expert in infectious diseases.

Paul’s impressive professional portfolio includes senior roles such as Professor at The University of Queensland, as well as the Director of Infectious Diseases at the Mater Hospital. Paul holds notable qualifications, including a BS (Hons) in Microbiology and Immunology, an MBBS, and fellowships in Infectious Diseases and clinical microbiology.

Principal Medical Consultant

Dr Maria Beatrice Panico is a Principal Medical Consultant at Scendea, responsible for providing high-quality technical advice and product development strategies to our clients and Scendea team. Beatrice was formerly a Leading Senior Medical Assessor at the MHRA and represented the UK in the European working groups on new trial designs, safety and In Vitro Diagnostics. She is one of the authors of the CTFG Recommendation Paper on the Initiation and Conduct of Complex Clinical Trials.

Prior to joining the MHRA, Beatrice worked as a clinical neurologist, clinical investigator, researcher in neuroscience and pharmacovigilance expert in the pharmaceutical industry. Beatrice is a member of the WHO working group on regulatory aspects of artificial intelligence and is the 2023 TOPRA awards for regulatory excellence ‘Lifetime Achievement’ award winner. Beatrice is a medical doctor, fully qualified neurologist and has a PhD in neuroscience.

Principal Medical Consultant

Dr Austin Smith is a Principal Medical Consultant at Scendea, responsible for providing technical, scientific and clinical development advice to our clients. Austin has 15 years of experience in clinical practice in both radiation and medical oncology and over 20 years in pharmaceutical industry covering all aspects of clinical development.

Austin has extensive knowledge in a wide range of therapeutic areas. However, Austin has a particular peak of knowledge in the oncology and immunology space having practiced as a medical oncologist. Austin has held a variety of industry positions including at PPD, Theradex, Nanomab Technologies and LINK Medical. Austin has a Doctor of Medicine from the Royal College of Surgeons (Ireland) and is General Medical Council (UK) certified.

Head of Non-Clinical and Principal Consultant

Dr Angeles Escarti-Nebot is Head of Non-Clinical and Principal Consultant at Scendea with experience in the initiation, management and execution of regulatory projects from early development to marketing authorisation. Angeles has previously held positions in Paraxel and PhamaLex and her areas of expertise include regulatory strategy, non-clinical and quality development programs for the EU and US markets.

Angeles has a strong scientific background with more than seven years’ experience on biotechnology research and more than 10 years’ experience in a regulatory environment. Angeles holds a PhD in molecular biology (gene and cell-based therapies), BA in Pharmacy, MS in Clinical Genetics and MS in Neuropharmacology.

Head of CMC & Principal Consultant

Dr James Parsley is Head of CMC & Principal Consultant at Scendea. James is responsible for providing global CMC biological technical and regulatory advice to clients from early-stage development through to marketing authorisation and post marketing.

A former director at GSK, James has 20 years’ experience in the pharmaceutical industry with a broad regulatory background in terms of regulatory disciplines and therapeutic areas. His main expertise is in CMC biopharmaceuticals. James holds a DPhil in Biochemistry from the University of Sussex and is a member of TOPRA for which he has previously lectured on both nonclinical and CMC biopharmaceutical regulatory affairs.

Technical Head (NL) & Principal Consultant

Erik Doevendans is Technical Head NL & Principal Consultant at Scendea. Erik has expertise in the full range of EU/US product development and regulatory projects undertaken at Scendea. Erik’s strength is in CMC and regulatory strategy associated with biologics. Erik also has expertise in the field of Quality Assurance.

Erik has over 20 years’ industry experience in the pharmaceutical industry holding positions at Pharming, Xendo and Dopharma. Erik was previously a Pharmaceutical Assessor at the Dutch MEB, and an expert to the EMA. Erik holds a degree in Pharmacy.

Technical Head (AUS) & Principal Consultant

Penny Field is Technical Head (AUS) & Principal Consultant at Scendea, responsible for providing regulatory, CMC and clinical development strategies to clients. Penny has over 30 years’ regulatory experience in the development and registration of biopharmaceuticals including prophylactic and immunotherapeutic vaccines, recombinant proteins (including mAB and biosimilars) and cell and gene therapies and has provided regulatory strategy, clinical guidance and scientific advice for a range of complex biologicals.

Penny has worked with CSL, Amgen and ERA Consulting and has also consulted to more than 30 companies to facilitate the product development and registration of prescription medicines. Penny holds a BSc (Hons) in Biotechnology and a MMSc in Drug Development.

Principal Consultant

Dan Cafaro is a Principal Consultant at Scendea responsible for defining and executing strategy for global regulatory affairs for medicinal products. Dan has extensive experience interacting with the FDA and the EMA and has over 30 years’ experience in managing worldwide regulatory and development programs in the pharmaceutical and biotechnology industries.

Dan has held several senior leadership roles at Quark Pharmaceuticals, XOMA and Allergan and belongs to several professional societies including the Regulatory Affairs Professional Society (RAPS), The Organisation for Professionals in Regulatory Affairs (TOPRA), the Drug Information Association (DIA). Dan holds a BSc in Chemistry.

Principal Consultant

Igor Gonda is a Principal Consultant at Scendea responsible for providing technical/regulatory advice and product development strategies. Igor has over 40 years’ experience in all aspects of pharmaceutical product development including extensive experience interacting with the FDA and EMA as well as patient advocacy groups. Igor has held a variety of executive positions including at Genentech, Acrux and Aradigm.

Igor has an in-depth understanding of inhalation product development and has significant experience in the respiratory and infectious disease fields. Igor holds a BSc in Chemistry, a PhD in Physical Chemistry and has conducted inhalation product research and lectured at several universities in the USA, Europe and Australia.

Principal Consultant

Dr Asha Kattige is a Principal Consultant at Scendea, responsible for providing technical advice in the areas of CMC, product development and international regulatory affairs, to facilitate the entry of clients’ compounds into clinical trials and assist in the activities required for successful international marketing approvals.

Asha has over 20 years’ experience in the pharmaceutical industry, holding senior positions at various companies including UCB, Teva, Quotient Sciences and Patheon. Asha has substantial experience in the fields of CMC, Product Development and Regulatory Affairs. Asha holds a PhD in Pharmaceutical Technology, has conducted research in parenteral and inhalation products and presented at various conferences.

Principal Consultant

Stephen Kirk is a Principal Consultant at Scendea, responsible for providing nonclinical scientific and regulatory advice to our clients. Stephen was formerly head of nonclinical science at Allergy Therapeutics and prior to this, spent over two years as a senior toxicologist in the research and development group at KalVista Pharmaceuticals. Before joining the pharmaceutical industry Stephen spent over 20 years in various contract research organisations (Including Covance, Charles River and Aptuit) as a study director In toxicology and Immunotoxicology.

Stephen has a strong scientific background with more than 25 years experience In drug development. Stephen holds a BSc (Hons) in Immunology and a post-graduate certificate In Biopharmaceutical Development.

Principal Consultant

Cynthia Lee is a principal consultant at Scendea. She specialises in auditing, providing training/coaching for API, finished product pharmaceutical and contract laboratories in cGMP manufacturing, laboratory, and Quality Assurance operations.

Cynthia has 30 years of experience in the pharmaceutical industry, 20 years of service with the FDA as a pharmaceutical chemist and investigative analyst and the past 10 years as an independent consultant active in assisting firms with corrective actions from FDA inspections, performing mock inspections and gap assessments, coaching prior to and during FDA inspections, and providing due diligence assessments. Cynthia holds a BSc in Chemistry and a MSc in Food Science and Technology.

Deputy Head of Product Development & Regulatory Consulting, Principal Consultant

Shweta Menon is the Deputy Head of Product Development & Regulatory Consulting, Principal Consultant at Scendea, responsible for providing company-wide operational leadership to project management teams alongside strategic, technical and regulatory advice and services to clients. Shweta has over 16 years’ experience working in regulatory affairs including roles in GSK, Hospira and Teva. Most recently Shweta held the position of Associate Program Director at Parexel.

Shweta has considerable experience in both pre- and post-authorisation submission activities in the EU and Global markets over a range of therapeutic areas for small molecules and biologics in addition to successfully project managing large scale partnerships and short-term engagements. Shweta holds a M.Pharm in Pharmaceutics.

Principal Consultant

Dr Patrizia Nestby is a Principal Consultant at Scendea with over 20 years’ experience in defining and executing strategy for global regulatory affairs for medicinal products. Patrizia has worked within industry and consultancy environments.

Patrizia is a biomedical scientist with a PhD in Neuropharmacology from the Free University of Amsterdam, The Netherlands. She has an MSc in Regulatory Affairs (completed with distinction) from the University of Cardiff. Patrizia is an Honorary Fellow of The Organisation of Professionals in Regulatory Affairs (TOPRA).

Principal Consultant

Aarti Pattni is a Principal Consultant at Scendea, responsible for the authoring and compilation of regulatory submissions to European and US agencies, in addition to providing strategic, technical and regulatory advice and services to clients within her role as project manager.

Aarti has experience working in various therapeutic areas including oncology and general medicines. Prior to joining Scendea, Aarti has been working with MSD in the Netherlands as an EU Liaison, Regulatory Affairs Europe, before this she worked for GSK, as a non-clinical Regulatory Associate and Regulatory Operations Associate in Ware and Stockley Park sites, respectively. Aarti holds a BSc in Biochemistry from King’s College London.

Principal Consultant

Dr Justine Ramsden is a Principal Consultant at Scendea responsible for providing high-quality regulatory CMC technical advice and product development strategies. Justine has over 25 years of experience in the pharmaceutical industry, including over 22 years in Regulatory Affairs and has held senior positions in pharmaceutical companies including Alliance Pharmaceuticals and Piramal Critical Care.

Justine has extensive experience interacting with various EU regulatory bodies and has considerable experience in both pre- and post-authorisation submission activities in the EU and Global markets over a range of dosage forms and therapeutic areas. Besides her core CMC expertise, she has extensive experience in CMC writing, and strategic guidance and holds a PhD in pharmaceutical drug development.

Principal Consultant

Dr Natalie Thomas is a Principal Consultant at Scendea. Natalie provides strategic regulatory, non-clinical and clinical development advice to clients in support of global development programmes. She currently sits on the Editorial Board of the regulatory professional journal, Regulatory Rapporteur.

Natalie began her career as a Research Scientist in the Australian Pharmaceutical industry. She moved into Medicinal Product Development and Regulatory Affairs consulting over ten years ago, working in roles at ERA Consulting and Voisin Consulting, prior to joining Clinical Network Services in 2014. Natalie holds a PhD in Biochemistry and Molecular Biology.

Principal Consultant

Ian Waterson is a Principal Consultant at Scendea, responsible for providing nonclinical scientific and regulatory advice to our clients. Ian was formerly a Senior Non Clinical Assessor at the MHRA and has previously held positions in Sanofi and Covance working both as a Study Director and Toxicology Project Team Representative.

Ian has a strong scientific background with more than 29 years’ experience in drug development and 8 years’ experience as a MHRA regulator. Ian holds an MSc in Applied Toxicology and a BSc (Hons) in Life Sciences.

Principal Consultant

Leanne West is a Principal Consultant at Scendea responsible for providing regulatory and clinical development strategies to clients. Leanne has over 28 years’ experience in the biotechnology, pharmaceutical and CRO industries. Leanne has a broad level of experience across all phases of drug development and project management. Therapeutic areas include Infectious disease, oncology, women’s health, cardiovascular disease and vaccines. Leanne has expertise in first-In-human trials and the regulatory hurdles required to move new agents into the clinic.

Leanne has held senior positions at Prescient Therapeutics, Novotech, Clinical Network Services and Novogen Limited and has also consulted multiple biotechnology companies to facilitate their clinical development. Leanne holds a BBiotechnology (Hons).

Principal Consultant

Dr Babaji Yadav is a Principal consultant at Scendea, responsible for providing strategic Nonclinical/toxicology and clinical development advice to clients in support of global development programmes. He has over eight years of academic experience in pre-clinical oncology drug development, and ten years of industry experience in early phase clinical development and nonclinical consulting.

Babaji has prior experience in the Pharmaceutical, Biotech, and Clinical Contract Research Organization (CRO) industries, having worked at companies such as Sanofi-Aventis, Kazia Therapeutics, IQVIA, Clinical Network Services, and Novotech. Babaji is a registered EU/UK toxicologist and serves as an independent reviewer toxicologist on the Bellberry Human Research Ethics Committee (HREC) in Australia. Babaji holds a PhD in Pharmacology and Toxicology.

Principal Consultant

Dr Dmitry Zamoryakhin is an accomplished R&D scientist with extensive experience in drug development, oncology, and rare diseases. Most recently, he served as Chief Scientific and Chief Medical Officer at Biodexa Pharmaceuticals, leading R&D functions across clinical and regulatory domains and advancing therapies for glioblastoma, paediatric brain tumours, and familial adenomatous polyposis through various development stages. 

Previously, Dmitry held leadership roles at Oxford Biomedica and Grunenthal, where he drove innovations in gene therapy and drug-device combinations. Dmitry holds an MD, an MBA from Warwick Business School, and a diploma in Pharmaceutical Medicine.

Senior Consultant

Iheoma Anosike is a Senior Consultant at Scendea, responsible for overseeing the completion of deliverables for a number of Scendea's clients. Alongside her role as project manager, Iheoma works on the full scope of EU and US regulatory activities, managing various agency interactions and authoring technical/scientific documents for submission to regulatory authorities.

Whilst studying for her Master's degree in Advanced Chemical Engineering from Imperial College London, Iheoma gained experience in pharmaceutical process engineering and development for the production of medicines. Iheoma holds a BSc (Hons) in Biochemistry from the University of Birmingham. Iheoma is also a Regulatory Affairs Certification (RAC) holder.

Team Lead (AUS) & Senior Consultant

Kelly Burns is Team Lead (AUS) & Senior Consultant at Scendea with over 8 years’ experience working on early-phase clinical studies. Kelly has worked on regulatory documents across a broad range of therapeutic areas including infectious disease, respiratory disease, haematology, oncology, neurology, and immunological disorders.

Kelly started her career as a research scientist in reproductive biology and worked in skin pathology and histology before moving into clinical research. Kelly holds a BSc (Med.Sci) from the University of Newcastle Upon Tyne with first class honours in Physiology.

Senior Consultant

Dr Caroline Keane is a Senior Consultant at Scendea with 20 years of experience working on both early and late-stage clinical programmes. Caroline has worked across a broad range of therapeutic areas including allergy and respiratory, Immunology, women's health and oncology and haematology.

Caroline started her pharmaceutical career at Pfizer, working as a clinical development manager and was most recently a senior clinical scientist in oncology at Roche. Caroline holds a PhD in Immunology from University College Dublin.

Senior Consultant

Polly Kennard is a Senior Consultant at Scendea. Polly is responsible for authoring and management of regulatory submissions to US and European agencies, as well as providing support to clients within her role as project manager.

Polly has many years of experience in pre-clinical drug development, in the CRO pharmaceutical and biotech industry. Polly is a UK and EU Registered Toxicologist, and has worked in a number of therapeutic areas including neurological, respiratory and infectious diseases. Polly holds a BSc (Hons) in Pharmacology from the University of Hertfordshire and is a Member of the Royal Society of Biology, British Toxicology Society and American College of Toxicology.

Team Lead (US) & Senior Consultant

Dr Hannah Lewis is Team Lead (US) & Senior Consultant at Scendea. With over 6 years’ experience working in regulatory affairs, Hannah provides strategic regulatory and clinical advice to clients for global development programmes. Within this role, Hannah is also responsible for the authoring and compilation of regulatory dossiers for submissions to US and European agencies, supporting the entry of client assets into clinical trials and for international marketing approvals. 

Hannah was previously a Manager in Clinical Regulatory Affairs at GSK, with a focus on post-approval activities, and holds a Regulatory Affairs Certification (RAC Drugs). Hannah has a PhD and MRes in Cardiovascular Research from King’s College London and has 5 years’ experience working in academic research.

Senior Consultant

Harriet Thomasson-Coombs is a Senior Consultant at Scendea. In her role as Senior Consultant, Harriet acts as project manager for our global clients, specialising in the preparation of CMC documents and interacting with key regulatory authorities on their behalf. Harriet has a wealth of experience in European and US procedures and enjoys supporting our clients in navigating these complex regulatory landscapes.

Prior to joining Scendea, Harriet gained experience as a Medicinal Chemist specialising in small molecule drug discovery. Harriet holds an Integrated Master’s Degree in Chemistry and a Regulatory Affairs Certification (RAC). Harriet won the 2023 TOPRA Horizon award for regulatory excellence.

Senior Consultant

Dr Andrew Senior is a Senior Consultant at Scendea responsible for authoring and management of deliverables for a number of Scendea's clients. Andrew has over 23 years’ experience in the pharmaceutical industry with over 15 years’ experience in clinical and regulatory document preparation for early and late phase clinical studies and in clinical study design.

Andrew started his career as a research chemist working in the development of new synthetic routes and production of active pharmaceutical ingredients before moving into clinical research. He previously held the position of Head of Medical Writing at MAC Clinical Research and holds a BSc (Hons) in Chemistry from the University of Huddersfield, as well as a PhD in Chemistry from the University of Leeds.

Senior Consultant

Ellen Wilkinson is a Senior Consultant at Scendea providing technical advice and product development strategies to facilitate the entry of products into clinical trials and assist with successful international marketing approvals.

Ellen previously worked at the MHRA as an Assessor for Lower Risk Clinical Trials and also as a Clinical Safety Scientist, working on pharmacovigilance activities for UK clinical trials. Prior to joining the MHRA, Ellen has experience working within in-vitro academic research for the University of Arizona, USA, and holds a BSc (Hons) in Biomedical Sciences from the University of Bath.

Consultant

Dr Bethany Aykroyd is a Consultant at Scendea providing product development and regulatory affairs consulting advice to support the development programmes of Scendea’s clients. Bethany is responsible for authoring and preparing a range of documents for US and European agencies, interacting with regulatory authorities on behalf of clients and supporting them in her role as project manager.

Bethany holds a BSc (Hons) in Biomedical Science from the University of Essex, as well as an MPhil in Clinical Science specialising in rare diseases and a PhD in Physiology, Development and Neuroscience from the University of Cambridge. Bethany is also a Regulatory Affairs Certification (RAC) holder.

Consultant

Dr Sinéad Blaber is a Consultant at Scendea, responsible for medical writing and regulatory consultancy activities. She has over thirteen years’ industry experience specialising in translational medicine. She is experienced in the design of clinical and non-clinical studies and in clinical and regulatory document preparation. She is passionate about driving the development of therapies with promise to cure or significantly improve patients’ quality of life.

She previously held the position of Director of Clinical Development and Medical Affairs at Regeneus. Sinéad has a Bachelor of Biotechnology from the University of Technology, Sydney and a PhD in biotechnology from Macquarie University.

Consultant

Dr Sherry Liu is a Consultant at Scendea, responsible for preparing product development and technical/regulatory documentation, liaising with clients and regulatory authorities, and managing projects across Scendea's global portfolio, all while maintaining a high calibre of scientific and medical knowledge.

 Sherry possesses diverse industry experience, from medical device manufacturing to grant application development and consulting. Her academic research track record showcases expertise in translational biomaterials and recombinant therapeutics for chronic conditions including kidney disease and osteoarthritis. Sherry holds a BSc In Materials Science & Engineering from Cornell University and a PhD in Bioengineering from the University of Washington.

Consultant

Ellie McNamee is an Associate Consultant at Scendea. Ellie is responsible for the authoring and compilation of regulatory submissions to European and US agencies and is also involved in creating weekly regulatory intelligence briefing reports which summarise the latest guidelines and news from various parts of the world.

Prior to joining Scendea, Ellie gained experience working in an academic research facility and contributed to a pre-clinical study within the area of infectious disease. Ellie holds an Integrated Master's degree in Biomedical Science from the University of Southampton.

Consultant

Dr Leticia Monjas-Gómez is a Consultant at Scendea. Leticia is responsible for the authoring and compilation of regulatory submissions to European and US agencies, in addition to providing consulting and procedural support to clients within her role as project manager.

Leticia has experience in drug discovery from several academic research laboratories. She worked in various therapeutic areas including metabolic and infectious diseases. Leticia holds a MSc in Organic Chemistry from the Complutense University of Madrid (Spain), and a PhD in Medicinal Chemistry from the University of Groningen (The Netherlands). Leticia is also a Regulatory Affairs Certification (RAC) holder.

Consultant

Badrudiin Olow is a Consultant at Scendea. Badrudiin is responsible for the authoring and compilation of regulatory submissions to European and US agencies and is also involved in creating weekly regulatory intelligence briefing reports which summarise the latest guidelines and news from various parts of the world.

Prior to joining Scendea, Badrudiin gained experience working for the local council as a COVID-19 test operative. Badrudiin holds a BSc (Hons) in Biochemistry and a MSc in Molecular Biology and Biotechnology from the University of Sheffield.

Consultant

Aylin Pelut is a consultant at Scendea, responsible for providing regulatory technical advice and product development strategies for Scendea’s clients. Aylin works on the full scope of EU and US regulatory activities, managing various agency interactions and authoring technical/scientific documents for submission to regulatory authorities.

Prior to joining Scendea, Aylin gained experience within the pharmaceutical industry as a regulatory affairs specialist and has a deep understanding of the development process, from preclinical research to drug regulation and safety. Aylin holds a BSc in Biochemistry from the University of East Anglia and an MRes in Clinical Drug Development from the University College London.

Associate Consultant

Mauricio Cano is an Associate Consultant at Scendea. Mauricio is responsible for the authoring and compilation of regulatory submissions to the relevant regulatory agencies, in addition to providing consulting and procedural support to clients within his role as project manager.

Prior to joining Scendea, Mauricio worked at the Mexican branch of the pharmaceutical company Abbott Laboratories in the Quality Assurance department. He was responsible for diverse tasks to ensure compliance with the corresponding sanitary and regulatory authorities. Mauricio holds a BSc In Chemistry, Pharmacy & Biotechnology from Universidad del Valle de México and an Msc in Molecular Biology Research Extensive from the University of Queensland.

Associate Consultant

Brenna Devlin is an Associate Consultant at Scendea, responsible for authoring and compiling regulatory submissions and providing comprehensive product development support within the biotech and pharmaceutical industries. Brenna brings several years of experience in multidisciplinary project teams in academic research laboratories. She specialises in advanced biomedical engineering applications, including high-precision additive manufacturing, biomaterial development and software creation. 

Brenna holds a BEng in Mechanical Engineering from the University of the Sunshine Coast and is under examination for her PhD in Biomedical Engineering at the Queensland University of Technology.

Associate Consultant

Basia Grodyńska is an Associate Consultant at Scendea. Basia is responsible for the authoring and compilation of regulatory submissions to European and US agencies, in addition to providing consulting and procedural support to clients within her role as project manager.

Basia has experience in science research, communications, and writing, with emphasis on microbiology, virology, phylogenetics and phylodynamics. She has worked to encourage greater career interest in STEM subjects, especially among women. Basia holds a BSc (Hons I) in Human Biology from Queen Margaret University and an MSc in Evolutionary Genetics from the University of Edinburgh.

Associate Consultant

Nohman Mohammad is an Associate Consultant at Scendea. Nohman is responsible for authoring and compiling regulatory submissions to European and US agencies and being involved in creating weekly regulatory intelligence briefing reports which summarise the latest guidelines and news from various parts of the world.

Prior to joining Scendea Nohman gained experience as a COVID-19 PCR Scientist at Cignpost Diagnostics and before then working at a CRO called Covance Labcorp as a Bioanalytical Study Analyst. Nohman holds a BSc (Hons) in Biochemistry and a MSc in Immunology & Immunotherapy.

Associate Consultant

Dr Hamish Poli is an Associate Consultant at Scendea, responsible for the authoring and compilation of regulatory submissions as well as providing comprehensive product development support within the biotech and pharmaceutical industries.

Hamish has 6 years of experience in academic research laboratories developing drug delivery systems and tissue engineering platforms. He previously held academic teaching positions in undergraduate chemistry at The University of Queensland and is an active member of the Royal Australian Chemical Institute. He holds a BSc(Hons I) and PhD in chemistry from the University of Queensland. 

Associate Consultant

Dr Demi Wiskerke is an Associate Consultant at Scendea. Demi is tasked with providing high-quality technical support and product development strategies to clients throughout the process of entering compounds into clinical trials. She also assists with requirements for international marketing approvals.

Demi has several years of experience in cancer research at academic laboratories. She has worked in the biotech industry developing (pre-)clinical testing strategies and assisting with observational clinical trials. Demi holds an MRes in Cancer Biology from Imperial College London and a PhD in Tumour Biology from Queen Mary, University of London.

Associate Consultant

Dr Tulasi Yadati is an Associate Consultant at Scendea. Tulasi is responsible for the authoring and compilation of regulatory submissions to European and US agencies, in addition to providing consulting and procedural support to clients within her role as project manager.

Prior, Tulasi worked as research manager and medical writer for clients in the field of aesthetic medicine. She has experience in pre-clinical drug discovery from several academic institutions focusing on metabolic diseases. Tulasi holds an Msc in Animal Biotechnology and a PhD in Biomedical Sciences from the Maastricht University.

Associate Consultant Intern

Savannah is an Associate Consultant Intern at Scendea, responsible for the authoring and compilation of regulatory submissions to European and US agencies.

Savannah has previous experience as a bioanalytical chemist and as a research and development chemist working on high-tech coatings. Savannah holds a BSc in Chemistry from San Diego State University and will complete a MSc in Regulatory Science in December 2024.

Director

Paul Cronin is a Director and an integral member of the leadership team at Scendea. Alongside his position as Director, Paul manages Scendea’s global business development team. Paul has over 20 years’ experience in the pharmaceutical industry holding senior positions at several regulatory and clinical research companies including ERA Consulting, SMERUD Medical Research and Diamond Pharma Services.

Paul began his pharmaceutical career as a Regulatory Affairs/Product Development Consultant, thereafter, moving into business and corporate development. Paul has several advisory board roles and holds degrees in Biochemistry and International Business and Management.

Chief Business Officer

Mike Mulcahy is the Chief Business Officer at Scendea, responsible for leading our growing business development team and defining Scendea’s global commercial strategy.

With over 30 years of experience working with international teams, Mike brings a wealth of expertise in strategic, technical, scientific, commercial, program, and business management for a broad range of technologies and services for therapeutic and medical device development, manufacturing, and supply for major markets. Mike holds an MBA and a BSc in Industrial Chemistry.

Business Development Director, Asia-Pacific

Mohammad (Mo) Asad is the Business Development Director, Asia-Pacific at Scendea, playing a pivotal role in bringing innovative Pharmaceutical and Biotechnology products to market. He has a decade of experience in the Life Sciences industry in the functions of Regional Sales Manager and Consultant at Cencora PharmaLex, various R&D functions including Bayer, and Co-founding a medical device start-up in the breast cancer space.

Mo is a guest lecturer at the University of Sydney and appointed Australian Chair of the Asia Regulatory Professional Association. He holds degrees in Biomedical Engineering and Mechanical Engineering from Australia, the US, and Singapore.

Regional Business Development Manager, Benelux & DACH

Wouter Stoffels is the Business Development Manager for the Benelux and DACH region at Scendea, responsible for identifying client needs and ensuring they receive tailored solutions for their product development and/or regulatory challenges.

Wouter has extensive commercial experience in the pharmaceutical and medtech industry holding various positions at Helm Medical GmbH, Helm AG, SOL Spa and Abbott, and has experience with tenders, contract negotiations, project management, and launch strategies. Wouter holds a degree in International Marketing.

Business Development Manager, UK & Nordics 

Leah Michie is the Business Development Manager at Scendea, responsible for engaging with new clients in the UK and Nordics to help shape their regulatory journey through development to commercialisation. 

Leah brings a wealth of experience in both pre- and post-authorisation product development and strategy. Before joining Scendea, Leah was a Business Development Specialist at Voisin Consulting Life Sciences, managing client relationships and delivering end-to-end regulatory support to Biotech, Pharma and Medtech companies. Previously, she held the position of Account Manager at Lucid Group, supporting global pharmaceutical companies with post-authorisation launch activities. Leah holds a BSc (Hons) in Physiological Sciences.

Business Development Support

John Cronin offers Business Development and UK Office Management support to Scendea. John assists the full range of Business Development activities undertaken by Scendea. John is involved in finance administration and a variety of special projects that drive the success of the company.

John brings over 35 years’ Commercial, Business Development, Marketing and Business Leadership experience to the company. John has held a number of senior positions at Sony BMG and Polygram before starting his own PR/Marketing and Management consultancy. John holds a degree from Edge Hill University.

Senior Marketing Manager

Becky Murphy is the Senior Marketing Manager at Scendea, responsible for the development and execution of comprehensive end-to-end marketing strategies. Becky leads our dynamic marketing team, overseeing all aspects of our marketing initiatives, and meticulously manages both organic and paid content campaigns, ensuring seamless integration and maximum impact.

With extensive experience in omni-channel marketing, copywriting, and branding, Becky brings a creative and strategic approach to her role. Having held several senior marketing positions within B2B organisations, she possesses a keen understanding of industry trends and best practices. Becky holds a BA (Hons) in Fashion, Communication, and Promotion.

Marketing Manager

Tom Allport is a Marketing Consultant at Scendea, responsible for the creation of all visual marketing collateral, from branding, web and print design, videography and content for Scendea’s social media channels.

Tom is a multi-disciplinary creative; a highly skilled photographer, videographer and graphic designer with a keen interest in branding and messaging, utilising his diverse skill set to deliver seamless designs within his creative marketing. Tom has held several Senior Graphic Designer positions alongside managerial roles and holds a BA in Graphic Design.

Marketing Executive

Charlotte Knight is the Marketing Executive at Scendea. Charlotte supports the Marketing team in developing and implementing Marketing strategies to ensure the effective promotion of Scendea and our service offering.

Prior to joining Scendea, Charlotte’s experience includes people management, development of communication strategies and the management of business operations to ensure KPI’s are met across the organisation. Charlotte holds a BA (Hons) in Fashion, Marketing and branding.

Marketing Assistant

Ella Hayles is the Marketing Assistant at Scendea, where she supports various marketing initiatives and campaigns to boost brand visibility and engagement.

With a tech industry background, Ella’s experience lies in crafting and executing innovative marketing strategies that consistently improve engagement metrics and deliver measurable outcomes. Ella's blend of practical experience and formal education equips her to drive impactful marketing efforts at Scendea, contributing to its growth and market presence. Ella holds a Digital Marketing Qualification from Multiverse.

Managing Director (UK & EK) & Chief Financial Officer

Charles Camp is Managing Director (UK & EK) &d Chief Financial Officer and a member of the leadership team at Scendea. Charles is responsible for Scendea’s back office functions in addition to the strategic financial aspects of the business.

Prior to joining Scendea, Charles’ experience includes international expansion, key financial analysis, strategic planning and system implementation, specialising in investment and scenario modelling. Charles has worked in both a technical and commercial capacity, relishing the problem solving obligations inevitable in all SME’s. Charles is a Chartered Global Management Accountant and holds a BA in Business Management.

Finance Manager

Josh Coyle is the Finance Manager at Scendea, assisting in the running and development of the financial operations of the company. In addition, he supports the company in a business partnering capacity.

Josh completed his accounting qualification alongside working at a Big 4 firm in corporates audit. During this time, he led several large teams on audit engagements from FTSE100 construction companies to large airlines. Josh is an ICAEW Chartered Accountant (ACA) and holds a BSc in Mathematics and Physics from the University of Surrey - having also spent time studying at Nanyang Tech. University, Singapore.

Trainee Chartered Accountant

Thomas Smith is a Trainee Chartered Accountant at Scendea and assists in the preparation of the management accounts and support of the wider accounting function for the company.

Before Scendea, Thomas gained his accounting expertise working for accountancy firms in and around London including a top ten and top fifty accountancy firm, where Thomas specialised in Tax. Thomas is a part-qualified ACCA Chartered Accountant and holds a BA (Hons) in Accounting and Finance from University of East London.

Executive Assistant

Kat Cash is the Executive Assistant at Scendea. Kat supports Paul Cronin and the entire C-Suite to strategically manage time with respect to priorities, goals, and objectives of Scendea, to enable efficient and effective senior leadership.

Prior to joining Scendea, Kat’s experience included account management and financial administration, specialising in the management of cash flow, project forecasts, budgets and overheads in addition to the streamlining of processes to increase efficiency and productivity. Kat holds a BSc (Hons) in Human Biology.

Business Support Manager

Jo Saward is the Business Support Manager at Scendea, responsible for working with internal and external stakeholders to deliver the company’s recruitment strategy along with providing administrative support to manage and facilitate efficient business development to ensure operational success.

Jo is an experienced Operations Manager who in her previous roles has specialised in writing and implementing recruitment processes, and effective onboarding and training programmes. Jo holds a BA in Drama and Classical Studies and a Level 5 Diploma in Human Resource Management.

Business Support Administrator

Lucie Compton is the Business Support Administrator at Scendea. Lucie works closely with several different departments to ensure efficient and effective operations.

Prior to joining Scendea, Lucie has worked in operations in the alcohol industry, and in product management in the furniture industry, with a strong focus on streamlining processes and implementing efficiencies to ensure effective workflow. Lucie holds a BA (Hons) in Marketing.

Operations Assistant

Maddy Johnson is the Operations Assistant at Scendea. Maddy provides the Operational team with administrative support to enable efficient and effective delivery of professional documents. Working across multiple projects within a global client base, Maddy ensures continuity across all company quality management systems and documents.

Prior to joining Scendea, Maddy’s experience includes quality management and administrating training platforms, quality supervision at a prestigious ski resort and admission coordination for an infusion service. Maddy holds a BA (Hons) in Politics and History.

Office Administrator

Tayla Teggart-Gonen is the Office Administrator at Scendea. Tayla works closely with various departments to ensure smooth day-to-day operations within the office, focusing on administrative support and office management.

Prior to joining Scendea, Tayla worked in an administration role at Tesco Plc, where she gained valuable experience in organisation and process management, as well as supporting the business within the various departments. Tayla is committed to fostering a well-organised and supportive environment within the office.

Managing Director (AUS) & Global Head of QA

Susan Jones is the Managing Director (AUS) & Global Head of QA at Scendea, responsible for the Quality Management System, process improvement including internal audits and leading the development of Scendea's training program.

Susan has over 25 years’ experience in the CRO industry, including various director roles in operations, quality and vendor management. Sue was the Director of Quality at CNS, where she established the quality group and was responsible for developing the QMS, training, and performing internal as well as local and international contracted audits. Sue holds a BAppSci and is a member of the RQA.

Senior Quality Associate

Fatin Izzati Mohd Khari is a Senior Quality Associate at Scendea. Fatin is responsible for performing internal audits activities, end-to-end management of quality documents and supporting the development of Scendea’s training program.

Fatin started her career in Quality for a major pharmaceutical company, supporting QMS activities including compliance with cGMP and training before moving to an international CRO where she was integral in initiating the vendor management function. Fatin holds a MSc In Medical Science and has experience working in CRO on vendor oversight and supporting the team with internal training activities.

Head of Human Resources

Zoe Jones works for Scendea as the Global Head of Human Resources. Zoe has over 18 years’ experience in Human Resources, previously working in Financial Services covering Europe, US and Asia.

Using her extensive operational and management experience, Zoe works alongside Scendea providing ongoing Human Resources support, in addition to providing operational leadership for Human Resources-related process and system optimisation. Zoe’s aim is to align team wellbeing to the overall business strategy. Zoe holds a degree in Human Resources.

HR Manager

Jo Childs works for Scendea as the HR Business Partner and is responsible for providing HR support, guidance and management training for our operations both on an operational and strategic level.

Jo has over 30 year’s experience working in Human Resources for a FTSE 100 online and store retailer, partnering directors and leading a team of HRBP's across the South East and South Coast. Her experience includes coaching for potential, leadership training and development, large scale change design and management, project management, resourcing and resource planning and building teams from scratch, to name a few. She is also a Chartered Member of the CIPD.

Global Head of Legal

Keith Vincent is a corporate solicitor. For over 20 years he has specialised in advising shareholders and board members on a broad range of corporate and commercial legal matters. During his career Keith has acted as a non-executive director and adviser to a number of different businesses in a variety of sectors, always adding sound commercial advice based on the years’ of experience he has working with entrepreneurs.

Keith is the founder and managing partner of the boutique commercial law firm Aquabridge Law, and in so doing supports Scendea with all aspects of commercial, corporate and employment law.